A phase II trial of CI-921 in advanced malignancies |
| |
| Authors: | Nancy T. Sklarin Peter H. Wiernik William R. Grove Laura Benson Abraham Mittelman Jean A. Maroun James A. Stewart Francisco Robert James H. Doroshow Peter J. Rosen Jacques Jolivet John C. Ruckdeschel Nicholas J. Robert Enrique Vèlez-Garcìa Daniel E. Bergsagel Lawrence C. Panasci Aletta M. van der Merwe Jacques J. Longueville Jane Leiby Charles D. Kowal |
| |
| Affiliation: | (1) Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY, USA;(2) Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY, USA;(3) Parke-Davis Pharmaceutical, Research Division of Warner-Lambert Company, Ann Arbor, MI, USA;(4) New York Medical Center, Valhalla, NY, USA;(5) Ottawa Regional Cancer Center, Ottawa, Canada;(6) Vermont Regional Cancer Center, Burlington, VT, USA;(7) San Juan Veterans Hospital, San Juan, P.R., USA;(8) City of Hope National Medical Center, Duarte, CA, USA;(9) University Southern California, Los Angeles, CA, USA;(10) Notre-Dame Hospital, Montreal, Canada;(11) Albany Medical College, Albany, NY, USA;(12) New England Medical Center, Boston, MA, USA;(13) School of Medicine, University of Puerto Rico, San Juan, P.R., USA;(14) Ontario Cancer Institute, Toronto, Canada;(15) Jewish General Hospital, Montreal, Canada;(16) Tygergbert Hospital, Parow, South Africa;(17) Cliniques Universitaires St-Luc, Brussels, Belgium;(18) Ohio State University Hospital, Columbus, OH, USA |
| |
| Abstract: | CI-921, (9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]-N,5-dimethyl-4-acridinecarboxamide 2-hydroxyethanesulfonate (1 1)), an anilinoacridine derivative with activity in experimental solid tumors was studied in a multicenter phase II trial in patients with solid tumors. Eligible tumor types included cancers of the breast, stomach, pancreas, nonsmall cell lung, small cell lung, colon, head and neck area, and melanoma. Prestudy requirements included an ECOG performance status of  2, no CNS metastases, and measurable disease. CI-921 was administered intravenously over 1–2 hours on days 1,8, and 15 of a 35-day course at an initial dose of 270 mg/M2, with modification in subsequent courses based upon tolerance. Principal toxicities included leukopenia, marked phlebitis, and mild nausea and vomiting. One hundred fifty patients were entered of whom 132 were evaluable for response. There was one complete and one partial response among 19 patients with breast cancer, and two partial responses, one each among 14 head and neck and 36 nonsmall cell lung cancer patients. |
| |
| Keywords: | CI-921 anilinoacridine |
| 本文献已被 SpringerLink 等数据库收录！ |
|
